MADRIGAL PHARMACEUTICALS, INC. Total Liabilities and Equity
MADRIGAL PHARMACEUTICALS, INC. (MDGL) had Total Liabilities and Equity of $1.24 billion as of 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Balance Sheet
us-gaap:LiabilitiesAndStockholdersEquity · last filed 2026-07-30
- 2026-06-30: Liabilities and Equity $1.24B.
- 2026-03-31: Liabilities and Equity $1.23B.
- 2025-12-31: Liabilities and Equity $1.26B.
- 2025-09-30: Liabilities and Equity $1.36B.
| Period end | Liabilities and Equity | Liabilities and Equity as first filed |
|---|---|---|
| 2026-06-30 | $1.24B 10-Q · filed 2026-07-30 | |
| 2026-03-31 | $1.23B 10-Q · filed 2026-05-06 | |
| 2025-12-31 | $1.26B 10-Q · filed 2026-07-30 | |
| 2025-09-30 | $1.36B 10-Q · filed 2025-11-04 | |
| 2025-06-30 | $1.02B 10-Q · filed 2025-08-05 | |
| 2025-03-31 | $996.63M 10-Q · filed 2025-05-01 | |
| 2024-12-31 | $1.04B 10-K · filed 2026-02-19 | |
| 2024-09-30 | $1.07B 10-Q · filed 2024-10-31 | |
| 2024-06-30 | $1.10B 10-Q · filed 2024-08-07 | |
| 2024-03-31 | $1.08B 10-Q · filed 2024-05-07 | |
| 2023-12-31 | $640.55M 10-K · filed 2025-02-26 | |
| 2023-09-30 | $237.96M 10-Q · filed 2023-11-06 | |
| 2023-06-30 | $302.46M 10-Q · filed 2023-08-08 | |
| 2023-03-31 | $332.45M 10-Q · filed 2023-05-09 | |
| 2022-12-31 | $362.57M 10-K · filed 2024-02-28 | |
| 2022-09-30 | $158.64M 10-Q · filed 2022-11-03 | |
| 2022-06-30 | $216.39M 10-Q · filed 2022-08-04 | |
| 2022-03-31 | $222.66M 10-Q · filed 2022-05-09 | |
| 2021-12-31 | $273.33M 10-K/A · filed 2023-03-03 | |
| 2021-09-30 | $304.70M 10-Q · filed 2021-11-04 | |
| 2021-06-30 | $327.95M 10-Q · filed 2021-08-05 | |
| 2021-03-31 | $309.73M 10-Q · filed 2021-05-06 | |
| 2020-12-31 | $287.00M 10-K · filed 2022-02-24 | |
| 2020-09-30 | $339.62M 10-Q · filed 2020-11-05 | |
| 2020-06-30 | $388.39M 10-Q · filed 2020-08-06 | |
| 2020-03-31 | $411.46M 10-Q · filed 2020-05-07 | |
| 2019-12-31 | $442.06M 10-K · filed 2021-02-25 | |
| 2019-09-30 | $456.25M 10-Q · filed 2019-11-06 | |
| 2019-06-30 | $469.82M 10-Q · filed 2019-08-07 | |
| 2019-03-31 | $479.56M 10-Q · filed 2019-05-08 | |
| 2018-12-31 | $485.43M 10-K · filed 2020-02-26 | |
| 2018-09-30 | $489.55M 10-Q · filed 2018-11-06 | |
| 2018-06-30 | $491.53M 10-Q · filed 2018-08-07 | |
| 2018-03-31 | $183.48M 10-Q · filed 2018-05-08 | |
| 2017-12-31 | $192.31M 10-K · filed 2019-02-27 | |
| 2017-09-30 | $62.83M 10-Q · filed 2017-11-09 | |
| 2017-06-30 | $68.07M 10-Q · filed 2017-08-10 | |
| 2017-03-31 | $40.36M 10-Q · filed 2017-05-11 | |
| 2016-12-31 | $41.21M 10-K · filed 2018-03-13 | $41.21M 10-K · filed 2017-03-31 |
| 2016-09-30 | $41.51M 10-Q/A · filed 2017-03-31 | |
| 2016-06-30 | $44.94M 10-Q · filed 2016-07-20 | |
| 2016-03-31 | $52.97M 10-Q · filed 2016-05-10 | |
| 2015-12-31 | $363.58K 10-K · filed 2017-03-31 | $68.19M 10-K · filed 2016-03-15 |
| 2015-09-30 | $91.01M 10-Q · filed 2015-11-05 | |
| 2015-06-30 | $101.54M 10-Q · filed 2015-08-06 | |
| 2015-03-31 | $79.39M 10-Q · filed 2015-05-07 | |
| 2014-12-31 | $100.67M 10-K · filed 2016-03-15 | |
| 2014-09-30 | $123.66M 10-Q · filed 2014-11-06 | |
| 2014-06-30 | $115.95M 10-Q · filed 2014-08-06 | |
| 2014-03-31 | $82.18M 10-Q · filed 2014-05-08 | |
| 2013-12-31 | $95.20M 10-K · filed 2015-03-12 | |
| 2013-09-30 | $56.66M 10-Q · filed 2013-11-04 | |
| 2013-06-30 | $73.92M 10-Q · filed 2013-08-01 | |
| 2013-03-31 | $93.70M 10-Q · filed 2013-04-30 | |
| 2012-12-31 | $103.02M 10-K · filed 2014-03-11 | |
| 2012-09-30 | $57.61M 10-Q · filed 2012-11-06 | |
| 2012-06-30 | $47.16M 10-Q · filed 2012-08-02 | |
| 2012-03-31 | $59.84M 10-Q · filed 2012-05-03 | |
| 2011-12-31 | $42.32M 10-K · filed 2013-03-14 | |
| 2011-09-30 | $53.87M 10-Q · filed 2011-11-03 | |
| 2011-06-30 | $65.62M 10-Q · filed 2011-08-04 | |
| 2010-12-31 | $54.07M 10-K · filed 2012-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |